Gastroenterology

News from the FDA/CDC

FDA approves subcutaneous infliximab for IBD

The new formulation was approved based on phase 3 pivotal trials that evaluated the safety and efficacy of infliximab-dyyb as maintenance therapy...

MD IQ

Pages